Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
16.72
-1.13 (-6.33%)
Sep 21, 2026, 2:01 PM EDT - Market open
Summit Therapeutics Employees
Summit Therapeutics had 265 employees as of December 31, 2025. The number of employees increased by 106 or 66.67% compared to the previous year.
Employees
265
Change (1Y)
106
Growth (1Y)
66.67%
Revenue / Employee
n/a
Profits / Employee
-$3,230,525
Market Cap
13.34B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 265 | 106 | 66.67% |
| Dec 31, 2024 | 159 | 54 | 51.43% |
| Dec 31, 2023 | 105 | 28 | 36.36% |
| Dec 31, 2022 | 77 | -33 | -30.00% |
| Dec 31, 2021 | 110 | 29 | 35.80% |
| Dec 31, 2020 | 81 | 11 | 15.71% |
| Dec 31, 2019 | 70 | 9 | 14.75% |
| Dec 31, 2018 | 61 | -15 | -19.74% |
| Dec 31, 2017 | 76 | 36 | 90.00% |
| Dec 31, 2016 | 40 | 3 | 8.11% |
| Dec 31, 2015 | 37 | 14 | 60.87% |
| Dec 31, 2014 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,000 |
| Jazz Pharmaceuticals | 2,890 |
| Axsome Therapeutics | 1,346 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| BridgeBio Pharma | 1,003 |
| Twist Bioscience | 979 |
SMMT News
- 6 days ago - Summit Therapeutics reports updated OS results from Phase 3 Harmoni trial - TheFly
- 6 days ago - Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients - Business Wire
- 8 days ago - Summit partner announces updated data from Phase III HARMONi-2 trial - TheFly
- 8 days ago - Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China - Business Wire
- 12 days ago - Summit Therapeutics upgraded to Buy at Jefferies ahead of PFS data - TheFly
- 12 days ago - Summit Therapeutics upgraded to Buy from Hold at Jefferies - TheFly
- 18 days ago - Summit Therapeutics Stock (SMMT) Rallies on Positive Clinical Trial Results - TipRanks
- 18 days ago - Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China - Business Wire